Tim de Waele/Velo by way of Getty Photographs
Novo Nordisk’s (NVO) has granted its CEO Lars Fruergaard Jørgensen a 13% increase for his efficiency in 2023, because the Danish drugmaker turned Europe’s most respected firm pushed by rising demand for its weight-loss medicine.
Jørgensen’s whole remuneration rose to DKK 68.2M (about $9.9M) final 12 months in comparison with DKK 60.1M in 2022, the corporate stated in its annual remuneration report.
“The remuneration degree is a results of strong enterprise outcomes and particular person efficiency by the CEO,” Novo (NVO) added, noting that the CEO’s base wage was elevated by 4% in keeping with different staff to account for wage inflation.
Nonetheless, Jørgensen’s short-term incentives for 2023 reached 96% of his most incentive, equaling 11.5 months of his base wage and up from 77% in 2022.
Whole remuneration for NOVO’s Govt Administration amounted to DKK 318.3M (about $46.0M) for 2023, a rise of ~22% from a 12 months in the past.
In 2023, Novo (NVO) reported DKK 232.3B (~$33.5B) in whole gross sales with a ~31% YoY progress pushed by its diabetes and weight problems care franchise, the place its widespread weight reduction remedy Wegovy added DKK 31.3B ($4.5B) with a 407% YoY progress.
